OIS@AAO 2017

Mitro Points Out Path to Aerie

By Mario Admin | December 17, 2017

In addition to bringing us up to date on Aerie Pharmaceuticals’ progress, Thomas A. Mitro, president and COO, sheds some light on his path to…

Read More

Hess Highlights Surging Platforms at Bausch + Lomb

By Mario Admin | December 17, 2017

Chuck Hess, vice president and general manager at Bausch + Lomb, updates us on the company’s growing Stellaris Elite and Vitesse platforms as well as…

Read More

Mitchell Sees Strong Growth at AcuFocus

By Mario Admin | December 17, 2017

Yari Mitchell, vice president of medical affairs and business strategy at AcuFocus, updates OIS.TV on the progress of the Kamra Inlay and the promise of…

Read More

Van Meter Says Ivantis Making Moves in MIGS

By Mario Admin | December 17, 2017

Dave Van Meter, president and CEO of Ivantis, explains how the company’s Hydrus Microstent plans to grab a piece of the growing MIGS market. He…

Read More

Frinzi Shares Milestones for Symfony, Looks at the Next Decade of Innovation

By Mario Admin | December 17, 2017

Thomas Frinzi, worldwide president, surgical, Johnson & Johnson Vision, shares some impressive milestones for the company’s Symfony and Symfony Toric IOLs. He also discusses the…

Read More

Iwach Delivers State of Glaucoma Therapy. What’s Next?

By Mario Admin | December 16, 2017

Few can track the past 10 years of advances in glaucoma treatment as well as Andrew Iwach, MD, executive director of the Glaucoma Center of…

Read More

Alimera Sees Bright Spots in 2018

By Mario Admin | December 16, 2017

Dan Myers, CEO of Alimera Sciences, says company growth is moving the firm into cash-positive territory in 2018. What challenges did he have to conquer…

Read More

CEO Roesky Sees Dry Eye Challenges as Opportunities for Novaliq

By Mario Admin | December 16, 2017

Christian Roesky, PhD, CEO and managing director of Novaliq GmbH, explains how the company’s water-free ophthalmic therapies can bring new treatments to ophthalmology’s most vexing…

Read More

Boorady Explains How TearScience Can Help “Bridge the O’s”

By Mario Admin | December 16, 2017

Joe Boorady, OD, president & CEO of TearScience, details the rollout of the company’s dry eye suite of tools now that it’s part of Johnson…

Read More

Gadek Compares, Contrasts SARcode and TearSolutions

By Mario Admin | December 16, 2017

Tom Gadek, president and CEO of dry eye start-up TearSolutions, explains how his “religious vision quest” at SARcode Bioscience, the entity that developed the drug…

Read More
Iconic

Iconic Eyes Phase IIb for Lead Candidate in 2018

By Mario Admin | December 15, 2017

Iconic Therapeutics is looking to take a significant step in ophthalmology in 2018, William Greene, MD, CEO, said during the Company Showcase 3 session at…

Read More
Private Funding Trends Presentation

SVB’s Norris Sees Surge in Strategics, Venture Dollars

By Mario Admin | December 12, 2017

Jonathan Norris, managing director at Silicon Valley Bank, points to increased fund-raising by healthcare-focused venture capital firms and a surge by strategic investors in Series…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.